vs
Coca-Cola Consolidated, Inc.（COKE）とSolventum（SOLV）の財務データ比較。上の社名をクリックして会社を切り替えられます
Solventumの直近四半期売上が大きい（$2.0B vs $1.9B、Coca-Cola Consolidated, Inc.の約1.0倍）。Coca-Cola Consolidated, Inc.の純利益率が高く（7.2% vs 3.2%、差は4.1%）。Coca-Cola Consolidated, Inc.の前年同期比売上増加率が高い（9.0% vs -3.7%）。Coca-Cola Consolidated, Inc.の直近四半期フリーキャッシュフローが多い（$106.7M vs $32.0M）。過去8四半期でCoca-Cola Consolidated, Inc.の売上複合成長率が高い（9.4% vs -0.4%）
コカ・コーラ・コンソリデーテッド社はノースカロライナ州シャーロットに本社を置く、アメリカ合衆国最大の独立系コカ・コーラボトラーです。同社はコカ・コーラ製品の製造・流通・地域販売促進を担当し、米国の飲料供給網において重要な役割を果たしています。
Solventum Corporationはアメリカ発祥のヘルスケア企業で、2024年4月1日に多岐にわたる事業を展開する世界的大手企業3Mからスピンオフして独立しました。旧3M医療部門の技術や事業資産を承継し、世界各国の顧客に医療関連の製品・サービスを提供しています。
COKE vs SOLV — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.9B | $2.0B |
| 純利益 | $137.3M | $63.0M |
| 粗利率 | 39.6% | 51.4% |
| 営業利益率 | 12.7% | 6.3% |
| 純利益率 | 7.2% | 3.2% |
| 売上前年比 | 9.0% | -3.7% |
| 純利益前年比 | -23.3% | 103.2% |
| EPS（希薄化後） | — | $0.37 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.9B | $2.0B | ||
| Q3 25 | $1.9B | $2.1B | ||
| Q2 25 | $1.9B | $2.2B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.7B | $2.1B | ||
| Q3 24 | $1.8B | $2.1B | ||
| Q2 24 | $1.8B | $2.1B | ||
| Q1 24 | $1.6B | $2.0B |
| Q4 25 | $137.3M | $63.0M | ||
| Q3 25 | $142.3M | $1.3B | ||
| Q2 25 | $187.4M | $90.0M | ||
| Q1 25 | $103.6M | $137.0M | ||
| Q4 24 | $178.9M | $31.0M | ||
| Q3 24 | $115.6M | $122.0M | ||
| Q2 24 | $172.8M | $89.0M | ||
| Q1 24 | $165.7M | $237.0M |
| Q4 25 | 39.6% | 51.4% | ||
| Q3 25 | 39.6% | 54.2% | ||
| Q2 25 | 40.0% | 54.4% | ||
| Q1 25 | 39.7% | 53.8% | ||
| Q4 24 | 40.0% | 53.9% | ||
| Q3 24 | 39.5% | 56.0% | ||
| Q2 24 | 39.9% | 54.6% | ||
| Q1 24 | 40.2% | 58.1% |
| Q4 25 | 12.7% | 6.3% | ||
| Q3 25 | 13.1% | 80.6% | ||
| Q2 25 | 14.7% | 9.9% | ||
| Q1 25 | 12.0% | 7.3% | ||
| Q4 24 | 12.5% | 6.6% | ||
| Q3 24 | 12.9% | 13.2% | ||
| Q2 24 | 14.4% | 11.7% | ||
| Q1 24 | 13.5% | 18.9% |
| Q4 25 | 7.2% | 3.2% | ||
| Q3 25 | 7.5% | 60.4% | ||
| Q2 25 | 10.1% | 4.2% | ||
| Q1 25 | 6.6% | 6.6% | ||
| Q4 24 | 10.2% | 1.5% | ||
| Q3 24 | 6.5% | 5.9% | ||
| Q2 24 | 9.6% | 4.3% | ||
| Q1 24 | 10.4% | 11.8% |
| Q4 25 | — | $0.37 | ||
| Q3 25 | — | $7.22 | ||
| Q2 25 | — | $0.51 | ||
| Q1 25 | — | $0.78 | ||
| Q4 24 | — | $0.18 | ||
| Q3 24 | — | $0.70 | ||
| Q2 24 | — | $0.51 | ||
| Q1 24 | — | $1.37 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $281.9M | $878.0M |
| 総負債低いほど良い | $2.8B | $5.0B |
| 株主資本純資産 | $-739.7M | $5.0B |
| 総資産 | $4.3B | $14.3B |
| 負債/資本比率低いほどレバレッジが低い | — | 1.00× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $281.9M | $878.0M | ||
| Q3 25 | $1.5B | $1.6B | ||
| Q2 25 | $1.2B | $492.0M | ||
| Q1 25 | $1.2B | $534.0M | ||
| Q4 24 | $1.1B | $762.0M | ||
| Q3 24 | $1.2B | $772.0M | ||
| Q2 24 | $1.7B | $897.0M | ||
| Q1 24 | $401.3M | $996.0M |
| Q4 25 | $2.8B | $5.0B | ||
| Q3 25 | $1.8B | $5.1B | ||
| Q2 25 | $1.8B | $7.8B | ||
| Q1 25 | $1.8B | $7.9B | ||
| Q4 24 | $1.8B | $8.0B | ||
| Q3 24 | $1.8B | $8.1B | ||
| Q2 24 | $1.8B | $8.3B | ||
| Q1 24 | $599.3M | $8.3B |
| Q4 25 | $-739.7M | $5.0B | ||
| Q3 25 | $1.6B | $5.0B | ||
| Q2 25 | $1.6B | $3.6B | ||
| Q1 25 | $1.5B | $3.3B | ||
| Q4 24 | $1.4B | $3.0B | ||
| Q3 24 | $1.3B | $3.2B | ||
| Q2 24 | $1.2B | $2.9B | ||
| Q1 24 | $1.6B | $3.9B |
| Q4 25 | $4.3B | $14.3B | ||
| Q3 25 | $5.7B | $14.0B | ||
| Q2 25 | $5.5B | $15.1B | ||
| Q1 25 | $5.4B | $14.5B | ||
| Q4 24 | $5.3B | $14.5B | ||
| Q3 24 | $5.3B | $14.7B | ||
| Q2 24 | $5.7B | $14.6B | ||
| Q1 24 | $4.3B | $14.7B |
| Q4 25 | — | 1.00× | ||
| Q3 25 | 1.09× | 1.03× | ||
| Q2 25 | 1.10× | 2.14× | ||
| Q1 25 | 1.19× | 2.43× | ||
| Q4 24 | 1.26× | 2.71× | ||
| Q3 24 | 1.39× | 2.54× | ||
| Q2 24 | 1.49× | 2.90× | ||
| Q1 24 | 0.37× | 2.16× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $209.0M | $95.0M |
| フリーキャッシュフロー営業CF - 設備投資 | $106.7M | $32.0M |
| FCFマージンFCF / 売上 | 5.6% | 1.6% |
| 設備投資強度設備投資 / 売上 | 5.4% | 3.2% |
| キャッシュ転換率営業CF / 純利益 | 1.52× | 1.51× |
| 直近12ヶ月FCF直近4四半期 | $619.6M | $-10.0M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $209.0M | $95.0M | ||
| Q3 25 | $316.7M | $76.0M | ||
| Q2 25 | $208.1M | $169.0M | ||
| Q1 25 | $198.2M | $29.0M | ||
| Q4 24 | $168.5M | $219.0M | ||
| Q3 24 | $270.8M | $169.0M | ||
| Q2 24 | $242.9M | $355.0M | ||
| Q1 24 | $194.3M | $442.0M |
| Q4 25 | $106.7M | $32.0M | ||
| Q3 25 | $264.1M | $-21.0M | ||
| Q2 25 | $148.5M | $59.0M | ||
| Q1 25 | $100.3M | $-80.0M | ||
| Q4 24 | $84.8M | $92.0M | ||
| Q3 24 | $142.8M | $76.0M | ||
| Q2 24 | $160.5M | $297.0M | ||
| Q1 24 | $117.2M | $340.0M |
| Q4 25 | 5.6% | 1.6% | ||
| Q3 25 | 14.0% | -1.0% | ||
| Q2 25 | 8.0% | 2.7% | ||
| Q1 25 | 6.3% | -3.9% | ||
| Q4 24 | 4.9% | 4.4% | ||
| Q3 24 | 8.1% | 3.7% | ||
| Q2 24 | 8.9% | 14.3% | ||
| Q1 24 | 7.4% | 16.9% |
| Q4 25 | 5.4% | 3.2% | ||
| Q3 25 | 2.8% | 4.6% | ||
| Q2 25 | 3.2% | 5.1% | ||
| Q1 25 | 6.2% | 5.3% | ||
| Q4 24 | 4.8% | 6.1% | ||
| Q3 24 | 7.2% | 4.5% | ||
| Q2 24 | 4.6% | 2.8% | ||
| Q1 24 | 4.8% | 5.1% |
| Q4 25 | 1.52× | 1.51× | ||
| Q3 25 | 2.22× | 0.06× | ||
| Q2 25 | 1.11× | 1.88× | ||
| Q1 25 | 1.91× | 0.21× | ||
| Q4 24 | 0.94× | 7.06× | ||
| Q3 24 | 2.34× | 1.39× | ||
| Q2 24 | 1.41× | 3.99× | ||
| Q1 24 | 1.17× | 1.86× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
COKE
| Transferred At Point In Time | $1.9B | 99% |
| Transferred Over Time | $15.1M | 1% |
SOLV
| Infection Prevention And Surgical Solutions | $752.0M | 38% |
| Cost Of Software And Rentals | $508.0M | 25% |
| Health Information Systems Segment | $347.0M | 17% |
| Dental Solutions Segment | $343.0M | 17% |
| Related Party | $14.0M | 1% |
